ArticleJournal of molecular modeling2026
Evaluation of Itraconazole as a repurposed small molecule inhibitor of EMT in breast cancer: a molecular docking and dynamics study.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextEpithelial-Mesenchymal Transition (EMT) is a critical driver of metastasis and drug resistance in breast cancer. Repurposing FDA-approved drugs offers a rapid strategy to target EMT pathways. This study evaluates Itraconazole, an antifungal agent with reported anti-cancer properties, as a potential multi-target inhibitor of the EMT signaling network. We investigated the binding mechanism and selectivity of Itraconazole against four key EMT regulators: Smoothened (SMO), TGF-βR1, EGFR, and GLI1. Our results identify SMO as the primary target, exhibiting high binding affinity and thermodynamic stability. Conversely, EGFR and GLI1 displayed significant structural instability, indicating a lack of direct inhibition. The study provides atomic-level structural evidence supporting the repurposing of Itraconazole as a selective, combinatorial therapeutic agent to target EMT-driven metastasis.
methodsInduced Fit Docking (IFD) was performed using the Schrödinger IFD protocol and the Glide XP scoring function within the Schrödinger Maestro suite. The dynamic stability of the protein-ligand complexes was evaluated using 500 ns molecular dynamics (MD) simulations with the Desmond software and the OPLS4 force field. To differentiate false positives and assess pose stability under enhanced sampling, Binding Pose Metadynamics (BPMD) was utilized. Thermodynamic binding free energies were calculated using the Thermal MM/GBSA method. All simulations were analyzed using the Simulation Interaction Diagram and trajectory clustering tools within Schrödinger.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.